Cuesta AM, Albiñana V, Gallardo-Vara E, Recio-Poveda L, de Rojas-P I, de Las Heras KVG, Aguirre DT, Botella LM  [2019]. The ß2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease

Albiñana V, Giménez-Gallego G, García-Mato A, Palacios P, Recio-Poveda L, Cuesta AM, Patier JL, Botella LM  [2019]. Topically Applied Etamsylate: A New Orphan Drug for HHT-Derived Epistaxis (Antiangiogenesis through FGF Pathway Inhibition)

González-Rodríguez B, Villar Gómez de Las Heras K, Aguirre DT, Rodríguez-Padial L, Albiñana V, Recio-Poveda L, Cuesta AM, Botella LM, Jiménez-Escribano RM  [2019]. Evaluation of the safety and effectiveness of oral propranolol in patients with von Hippel-Lindau disease and retinal hemangioblastomas: phase III clinical trial

Gallardo-Vara E, Tual-Chalot S, Botella LM, Arthur HM, Bernabeu C  [2018]. Soluble endoglin regulates expression of angiogenesis-related proteins and induction of arteriovenous malformations in a mouse model of hereditary hemorrhagic telangiectasia

Zarrabeitia R, Fariñas-Álvarez C, Santibáñez M, Señaris B, Fontalba A, Botella LM, Parra JA  [2017]. Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT). Health Qual Life Outcomes

Albiñana V, Escribano RMJ, Soler I, Padial LR, Recio-Poveda L, Villar Gómez de Las Heras K, Botella LM  [2017]. Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease

Díaz-Castellanos MA, Gómez de Las Heras KV, Díaz-Redondo T, González-Flores E, Albiñana V, Botella LM  [2017]. Case Report: Propranolol increases the therapeutic response to temozolomide in a patient with metastatic paraganglioma

Albiñana V, Zafra MP, Colau J, Zarrabeitia R, Recio-Poveda L, Olavarrieta L, Pérez-Pérez J, Botella LM  [2017]. Mutation affecting the proximal promoter of Endoglin as the origin of hereditary hemorrhagic telangiectasia type 1

Zarrabeitia R, Ojeda-Fernandez L, Recio L, Bernabéu C, Parra JA, Albiñana V, Botella LM  [2016]. Bazedoxifene, a new orphan drug for the treatment of bleeding in hereditary haemorrhagic telangiectasia

Ojeda-Fernández L, Recio-Poveda L, Aristorena M, Lastres P, Blanco FJ, Sanz-Rodríguez F, Gallardo-Vara E, de las Casas-Engel M, Corbí Á, Arthur HM, Bernabeu C, Botella LM  [2016]. Mice Lacking Endoglin in Macrophages Show an Impaired Immune Response

Botella LM, Albiñana V, Ojeda-Fernandez L, Recio-Poveda L, Bernabéu C  [2015]. Research on potential biomarkers in hereditary hemorrhagic telangiectasia

Albiñana V, Villar Gómez de Las Heras K, Serrano-Heras G, Segura T, Perona-Moratalla AB, Mota-Pérez M, de Campos JM, Botella LM  [2015]. Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients

Fontalba A, Fernández-Luna JL, Zarrabeitia R, Recio-Poveda L, Albiñana V, Ojeda-Fernández ML, Bernabéu C, Alcaraz LA, Botella LM  [2013]. Copy number variations in endoglin locus: mapping of large deletions in Spanish families with hereditary hemorrhagic telangiectasia type 1

Albiñana V, Recio-Poveda L, Zarrabeitia R, Bernabéu C, Botella LM  [2012]. Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia

Albiñana V, Sanz-Rodríguez F, Recio-Poveda L, Bernabéu C, Botella LM  [2011]. Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-ß1 signaling in endothelial cells

Albiñana V, Bernabeu-Herrero ME, Zarrabeitia R, Bernabéu C, Botella LM  [2010]. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells

Ojeda-Fernandez L, Barrios L, Rodriguez-Barbero A, Recio-Poveda L, Bernabeu C, Botella LM  [2010]. Reduced plasma levels of Ang-2 and sEng as novel biomarkers in hereditary hemorrhagic telangiectasia (HHT)

Botella LM, Sanz-Rodriguez F, Komi Y, Fernandez-L A, Varela E, Garrido-Martin EM, Narla G, Friedman SL, Kojima S  [2009]. TGF-beta regulates the expression of transcription factor KLF6 and its splice variants and promotes co-operative transactivation of common target genes through a Smad3-Sp1-KLF6 interaction